CP,I think in the past you may have mentioned expecting a final washout of retail before the pps starts to climb. I think this has been it. I will feel very badly for those that sell out at very low targets after years of waiting for this investment to mature. I really think this is just a bump in the road and probably good for us to focus on I/O rather than Docetaxel, but very painful nonetheless. Hoping this team shows Wednesday that they have learned something from the aftermath of 9/12 and have a viable plan in place to move forward as rapidly as possible.
CP, uncounted by you are the substantial numbers of shares we added in the last 10 days, mostly @$0.33-36/share, employing some of the STCG/LTCGs arising from OCAT buyout by Astellas. Leave it there for now.
Those results will be compared to HISTORICAL by a BP (they are not bound to apply the FDA rules) because BP will NOT want to take the risk that a result is GOOD because the CONTROL ARM UNDERPERFORMED. They know the drug has it value if it improves on the historical max. of 10 months and that it is WORTHLESS if it would have beaten a poor 7 months control arm by setting down 10 months.
Great point! investors should read and understand your logic.